Short answer
Nutex Health Inc. (NUTX) filed its Q2 2025 10-Q quarterly report on Nov 18, 2025 for the quarter ended Jun 30, 2025. Quarterly revenue was $244M (up 220.7% year over year) with net income of −$11M.
Q2 2025 key financials · XBRL
- Revenue
- $244M
- +220.7% YoY · +15.2% QoQ
- Net income
- −$11M
- −2952.9% YoY · −175.9% QoQ
- Operating margin
- 17.3%
- Gross margin
- 51.2%
- EPS (diluted)
- −$2.01
- −1335.7% YoY · −178.5% QoQ
Source: XBRL data from the Nutex Health Inc. (NUTX) Q2 2025 10-Q on SEC EDGAR. USD.
Nutex Health Inc. Q2 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Arbitration costs $48.0M for three months ended June 30, 2025
- Hospital division includes 24 facilities across 11 states
- Three new hospital facilities expected by end of 2025
- Regulatory changes and IDR litigation threaten reimbursement, revenue, and operating margins
Risk Factors
- New short-seller risk triggered by July 22, 2025 report, driving stock down 16.5% to $92.90
- New litigation risk from August–September 2025 securities class-action and derivative lawsuits
- Regulatory risk from potential SEC investigations following short-seller allegations
- Dilution risk: up to 1,051,924 shares, approximately 15.9% of current diluted shares
- Additional dilution risk: approximately 283,400 shares expected for four hospitals by December 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nutex Health Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.